Skip to main content
Signal8
Launch Terminal

RIGEL PHARMACEUTICALS INC (RIGL)

Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral interleukin receptor-associated kinases 1 and 4 (IRAK1/4) inhibitor, which is being advanced to Phase 1b study for the treatment of hematology-oncology, autoimmune, and inflammatory diseases, as well as to treat lower-risk myelodysplastic syndrome. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center (MDACC) for the development of olutasidenib in AML and other hematologic cancers with IDH1mutations; and the Collaborative Network for Neuro-Oncology Clinical Trial (CONNECT) to conduct a Phase 2 clinical trial to evaluate olutasidenib in combination with temozolomide in patients with high-grade glioma harboring an IDH1 mutation. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Rigel Pharmaceuticals, Inc. logo

Rigel Pharmaceuticals, Inc.

NASDAQ:RIGLHealthcare
-0.27%$51.31
AH$49.65-3.24%vs close
Mkt Cap$958.46M
Float16.73M
O/S18.68M
Vol
$ Vol
RVOL
Inst Own91.0%
SI16.3%
Earnings
Dilution
Rigel Pharmaceuticals, Inc. logoNASDAQ:RIGL$51.31-0.27%
Phase Distribution
28 lead-sponsored trials·5 active·19 completed
Phase 11
Phase 1/22
Phase 215
Phase 36
Phase 42
Not applicable2
(16 more as collaborator)
Status Overview
Recruiting5
Completed19
Stopped3
Expanded access1

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 4
    Recruiting

    Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies

    Olutasidenib, CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A4, and OATP1B1 Probe Substrates

    AML (Acute Myeloid Leukemia), Glioma +2

    Enrollment
    16
    Start
    Feb 2026
    Primary Completion
    Apr 2027est.
    Completion
    Jun 2027est.
    NCT07486713
  • Phase 4
    Recruiting

    Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid Tumors

    Pralsetinib, CYP3A4, CYP2C8, and CYP2C9 substrates, and hormonal contraceptive

    NSCLC (Non-small Cell Lung Cancer), Thyroid Cancer +2

    Enrollment
    12
    Start
    Mar 2026
    Primary Completion
    Jul 2027est.
    Completion
    Aug 2027est.
    NCT07704658
  • Phase 3
    Completed

    A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)

    Fostamatinib disodium, Placebo

    Immune Thrombocytopenic Purpura

    Enrollment
    76
    Start
    Jul 2014
    Primary Completion
    Apr 2016
    Completion
    Apr 2016
    NCT02076399
  • Phase 3
    Completed

    A Efficacy and Safety Study of Fostamatinib in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)

    Fostamatinib Disodium, Placebo

    Immune Thrombocytopenic Purpura

    Enrollment
    74
    Start
    Jan 2015
    Primary Completion
    Aug 2016
    Completion
    Aug 2016
    NCT02076412
  • Phase 3
    Completed

    Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)

    Fostamatinib Disodium

    Immune Thrombocytopenic Purpura

    Enrollment
    123
    Start
    Oct 2014
    Primary Completion
    Jun 2020
    Completion
    Jun 2020
    NCT02077192
  • Phase 3
    Completed

    A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of wAIHA

    Fostamatinib disodium, Placebo

    Warm Antibody Autoimmune Hemolytic Anemia

    Enrollment
    90
    Start
    Apr 2019
    Primary Completion
    Apr 2022
    Completion
    Apr 2022
    NCT03764618
  • Phase 3
    Enrolling by invitation

    A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia

    Fostamatinib disodium

    Warm Antibody Autoimmune Hemolytic Anemia

    Enrollment
    90
    Start
    Oct 2019
    Primary Completion
    Apr 2024est.
    Completion
    Apr 2024est.
    NCT04138927
  • Phase 3
    Completed

    Double-Blind, Randomized, Placebo-Controlled, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects

    Fostamatinib, Placebo

    Covid19, SARS (Severe Acute Respiratory Syndrome) +4

    Enrollment
    280
    Start
    Mar 2021
    Primary Completion
    Sep 2022
    Completion
    Sep 2022
    NCT04629703
  • Phase 2
    Completed

    7 Day Study of Mast Cell Inhibitor, R926112, in Patients With Symptomatic Seasonal Allergic Rhinitis

    R926112, Beclomethasone dipropionate

    Rhinitis, Allergic, Seasonal

    Enrollment
    375
    Start
    Jul 2005
    Primary Completion
    -
    Completion
    Sep 2005
    NCT00115089
  • Phase 2
    Completed

    Treatment of Arthritis With Syk Kinase Inhibition (TASKI-1)

    R788, Placebo

    Rheumatoid Arthritis

    Enrollment
    189
    Start
    Aug 2006
    Primary Completion
    Oct 2007
    Completion
    Dec 2007
    NCT00326339
  • Phase 2
    Completed

    Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis (Taski-3)

    Fostamatinib disodium (R935788), Placebo

    Rheumatoid Arthritis

    Enrollment
    219
    Start
    May 2008
    Primary Completion
    Jun 2009
    Completion
    Jun 2009
    NCT00665626
  • Phase 2
    Completed

    Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis

    Fostamatinib disodium (R935788), Fostamatinib disodium (R935788)

    Rheumatoid Arthritis

    Enrollment
    457
    Start
    May 2008
    Primary Completion
    Jun 2009
    Completion
    Jun 2009
    NCT00665925
  • Phase 2
    Completed

    Pilot Study of Fostamatinib Disodium/R935788 for the Treatment of Adult Refractory Immune Thrombocytopenic Purpura (ITP)

    Fostamatinib Disodium / R935788

    Purpura, Thrombocytopenic, Idiopathic

    Enrollment
    18
    Start
    Jan 2007
    Primary Completion
    Apr 2010
    Completion
    Apr 2010
    NCT00706342
  • Phase 2
    Withdrawn

    Efficacy and Safety Study of R935788 Tablets to Treat Systemic Lupus Erythematosus

    Fostamatinib Disodium (R935788), Placebo

    Systemic Lupus Erythematosus

    Enrollment
    0
    Start
    Nov 2008
    Primary Completion
    Nov 2009est.
    Completion
    Mar 2010est.
    NCT00752999
  • Phase 2
    Completed

    Efficacy and Safety Study of Fostamatinib Disodium Tablets to Treat T-Cell Lymphoma

    Fostamatinib Disodium

    T Cell Lymphoma

    Enrollment
    18
    Start
    Mar 2009
    Primary Completion
    Apr 2010
    Completion
    Apr 2010
    NCT00798096
  • Phase 2
    Completed

    A Safety and Efficacy Study of Inhaled R940343 in Patients With Mild to Moderate Asthma

    Placebo, R940343 1mg

    Asthma

    Enrollment
    301
    Start
    Jul 2012
    Primary Completion
    Jul 2013
    Completion
    Jul 2013
    NCT01591044
  • Phase 2
    Completed

    Safety and Efficacy of Topical R333 in Patients With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) Lesions

    R932333, Placebo

    Lupus Erythematosus, Discoid, Lupus Erythematosus, Systemic

    Enrollment
    54
    Start
    Aug 2012
    Primary Completion
    Sep 2013
    Completion
    Sep 2013
    NCT01597050
  • Phase 2
    Completed

    To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca

    R348 Ophthalmic Solution, 0.2%, R348 Ophthalmic Solution, 0.5%

    Keratoconjunctivitis Sicca

    Enrollment
    204
    Start
    Jul 2013
    Primary Completion
    Jul 2014
    Completion
    Jul 2014
    NCT01900249
  • Phase 2
    Completed

    Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graft Versus Host Disease Patients(DROPS-2)

    R348 Ophthalmic Solution, 0.2%, R348 Ophthalmic Solution, 0.5%

    Chronic Graft-versus-host Disease

    Enrollment
    35
    Start
    Mar 2014
    Primary Completion
    Jul 2016
    Completion
    Jul 2016
    NCT02040623
  • Phase 2
    Completed

    Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) Nephropathy

    Fostamatinib 150 mg, Fostamatinib 100 mg

    IGA Nephropathy

    Enrollment
    76
    Start
    Oct 2014
    Primary Completion
    Mar 2018
    Completion
    Nov 2018
    NCT02112838
  • Phase 2
    Withdrawn

    Open Label Study of Fostamatinib in the Treatment of IgA Nephropathy

    Fostamatinib Disodium tablet 100 mg, Fostamatinib Disodium tablet 150 mg

    IGA Nephropathy

    Enrollment
    0
    Start
    Sep 2015
    Primary Completion
    Sep 2015
    Completion
    -
    NCT02433236
  • Phase 2
    Completed

    A Safety and Efficacy Study of R935788 in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (AIHA)

    Fostamatinib 150 mg bid

    Warm Antibody Autoimmune Hemolytic Anemia

    Enrollment
    26
    Start
    Jul 2016
    Primary Completion
    Dec 2019
    Completion
    Dec 2019
    NCT02612558
  • Phase 2
    Recruiting

    Study of Olutasidenib and Temozolomide in HGG

    Olutasidenib + TMZ

    High Grade Glioma, Astrocytoma +17

    Enrollment
    60
    Start
    Feb 2025
    Primary Completion
    Jun 2029est.
    Completion
    Jun 2035est.
    NCT06161974
  • Phase 1/2
    Completed

    Efficacy and Safety Study of Fostamatinib Tablets to Treat B-cell Lymphoma

    fostamatinib

    Lymphoma

    Enrollment
    81
    Start
    Apr 2007
    Primary Completion
    Apr 2010
    Completion
    Oct 2010
    NCT00446095
  • Phase 1/2
    Recruiting

    Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)

    R906289 Monosodium (R289 Na)

    Low Risk Myelodysplastic Syndromes

    Enrollment
    86
    Start
    Sep 2022
    Primary Completion
    Aug 2026est.
    Completion
    Dec 2026est.
    NCT05308264

1-25 of 28

Search ClinicalTrials.gov for “Rigel Pharmaceuticals”